Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOther Accumulated ExpensesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Bioregenx (BRGX) Total Current Liabilities (2021 - 2025)

Bioregenx has reported Total Current Liabilities over the past 5 years, most recently at $4.1 million for Q4 2025.

  • For Q4 2025, Total Current Liabilities rose 11.92% year-over-year to $4.1 million; the TTM value through Dec 2025 reached $4.1 million, up 11.92%, while the annual FY2025 figure was $4.1 million, 11.92% up from the prior year.
  • Total Current Liabilities for Q4 2025 was $4.1 million at Bioregenx, up from $3.9 million in the prior quarter.
  • Over five years, Total Current Liabilities peaked at $4.1 million in Q4 2025 and troughed at $14159.0 in Q4 2021.
  • A 5-year average of $2.3 million and a median of $3.4 million in 2024 define the central range for Total Current Liabilities.
  • Biggest five-year swings in Total Current Liabilities: surged 8553.83% in 2024 and later grew 11.81% in 2025.
  • Year by year, Total Current Liabilities stood at $14159.0 in 2021, then soared by 358.22% to $64880.0 in 2022, then soared by 4195.9% to $2.8 million in 2023, then surged by 30.35% to $3.6 million in 2024, then rose by 11.92% to $4.1 million in 2025.
  • Business Quant data shows Total Current Liabilities for BRGX at $4.1 million in Q4 2025, $3.9 million in Q3 2025, and $3.9 million in Q2 2025.